Natural killer cell therapy (CYNK-001) granted Fast Track designation in the US for the treatment of recurrent glioblastoma multiforme

CYNK-001, a cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, is currently being investigated in a Phase I clinical trial for glioblastoma multiforme, a grade IV aggressive malignant brain tumour associated with poor prognosis.

Source:

Biospace Inc.